International Clinical Trial: Irinotecan Liposome (II) Combined with Capecitabine and Sintilimab Sequenced with Short-Course Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-Arm, Exploratory Clinical Study

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128864) titled 'Irinotecan Liposome (II) Combined with Capecitabine and Sintilimab Sequenced with Short-Course Radiotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-Arm, Exploratory Clinical Study' on July 27.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Drum Tower Hospital

Condition: Treatment-naive patients with locally advanced rectal adenocarcinoma without prior exposure to any antitumor therapy.

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2026-07-31

Target Sample Size: Neoadjuvant NALIRI-CAP and sintilimab followed b...